表紙
市場調査レポート

医薬器具リーダーシリーズ:薬剤充填済み注射器の主要製造業者

Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2014-2024

発行 Visiongain Ltd 商品コード 234469
出版日 ページ情報 英文 183 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=141.49円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬器具リーダーシリーズ:薬剤充填済み注射器の主要製造業者 Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2014-2024
出版日: 2014年04月24日 ページ情報: 英文 183 Pages
概要

世界における薬剤充填済み注射器の総収益は2018年には59億ドルの規模に達すると予測されています。また、売上は2024年に向けてさらに拡大する見通しです。生物製剤やワクチンの利用拡大が非経口投与の需要を押し上げており、特に、不安定な薬剤や他の複雑な薬剤に向けたプラスチック注射器やすぐに使える容器など、多くの市場機会が存在します。

当レポートでは、薬剤充填済み注射器の主要製造業者について調査し、業績、インタビュー、動向、機会および収益予測を提供しており、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 薬剤充填済み注射器市場

  • 薬剤充填済み注射器とは
  • 薬剤充填済み注射器メーカーの分類
  • ペン型注射器と自動注射器
  • 薬剤充填済み注射器のメリット・デメリット
  • 世界市場
  • 市場予測
  • 先進国での大きな需要
  • 市場成長推進因子・阻害因子

第3章 薬剤充填済み注射器の主要メーカー

  • Becton, Dickinson & Co (BD)
  • Gerresheimer
  • Schott
  • ニプロ
  • Stevanatoグループ
  • Unilife Corporation
  • ポーターのファイブフォース分析

第4章 薬剤充填済み注射器コンポーネントの主要メーカー

  • Aptar Stelmi:医薬品パッケージングの専門企業
  • Datwylerグループ
  • West Pharmaceutical Services
  • ポーターのファイブフォース分析

第5章 薬剤充填済み注射器の主要な委託製造業者

  • Catalent:世界最大のCMO
  • Hospira One2One
  • Vetter Pharma
  • Baxterの自社CMO
  • Laboratorios Farmaceuticos ROVI
  • Albany Molecular Research Inc (AMRI)
  • ポーターのファイブフォース分析

第6章 ペン型注射器・自動注射器の主要メーカー

  • Ypsomed:25年以上の経験を持つ糖尿病専門の業者
  • Haselmeier:自己注射器の専門業者
  • SHL Group
  • Owen Mumford
  • ポーターのファイブフォース分析

第7章 リサーチインタビュー

  • Simon Williams氏(Business Development at Duoject Medical Systems, カナダ)
  • 某主要メーカー

第8章 結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Pre-filled syringes and related devices - discover leading companies' revenue prospects

How are companies in the pre-filled syringe industry performing? Visiongain's report gives you data, analysis and discussions for producers of those drug delivery devices.

Our updated study lets you assess companies in the pre-filled (ready-to-fill) syringe industry and market, showing you their prospects to 2024. There you see financial results, interviews, trends, opportunities and sales predictions.

That way you discover potentials of established and emerging companies. Read on to scan those organisations and see what their future market could be worth.

Forecasts and discussions to help you stay ahead in knowledge and authority

Our new study assesses 19 top companies - and analyses that overall industry - with recent results, revenue forecasts and growth rates. There you gain 76 tables, 43 charts and two interviews.

You also get qualitative analyses, including research and development (R&D). Our work lets you assess the most lucrative applications of those drug delivery technologies. You see opportunities for biological drug makers and suppliers of medical injection devices.

That way you stay ahead in knowledge of the industry and market for these medical devices, helping your influence:

  • Plastic syringes
  • Glass syringes
  • Related injection products and disposable (single-use) systems for injecting drugs.

And the following sections highlight what our new investigation gives you.

Company profiles - what firms hold most potential and how do they succeed?

Our report profiles 19 leading companies across four sectors of the pre-filled injection devices market. The content of each discussion differs, depending on the company. In general, then, a profile contains the following information:

  • Overview of the firm, including its history in the pre-filled injection devices market
  • Discussion of the company's pre-filled injection device product or service portfolio, including main clients
  • Analysis of the company's recent financial performance, for overall revenue and, where possible, pre-filled injection device sales
  • Assessment of its recent developments there - e.g. acquisitions, expansions, launches and collaborations with the pharmaceutical industry
  • Prospects of the company - strengths over competitors and opportunities for sales
  • Prediction of revenue for the period 2014-2024 (for nine companies).

Those surveys show how product and service demand has changed in recent years, as well as explaining how those needs change from 2014.

Prospects for leading pre-filled syringe manufacturers

That study gives you discussions and financial analyses for leading developers and producers of pre-filled syringes:

  • Becton, Dickinson & Co. (BD)
  • Gerresheimer
  • Schott
  • Nipro
  • Nuova Ompi
  • Unilife Corporation.

There you discover what the future holds for those pharma-related medical device companies, seeing how they compare and compete. You find where the best prospects for business exist.

Suppliers and users of pre-filled injection systems will benefit from 2014. Next, our work analyses developers, producers and providers of associated technology.

Outlooks for manufacturers of pre-filled syringe components

The report shows you developments and revenue prospects for leading producers of syringe components:

  • Aptar Stelmi
  • Datwyler Group
  • West Pharmaceutical Services.

There you explore opportunities for companies making plungers, needle shields, tip caps and related products.

Hear where the money lies. Our work shows you where sales growth can occur. Many opportunities remain, with expanding revenues likely from 2014 to 2024.

Potentials of leading pen injector and autoinjector producers

In our study you also see commercial outlooks for top manufacturers of pen injectors and autoinjectors:

  • Haselmeier
  • Owen Mumford
  • SHL Group
  • Ypsomed.

There you assess product portfolios, strategies and revenue prospects. You also investigate associated organisations and competition. Our work shows you possibilities for advancing technologies and raising sales.

Contract manufacturers in that parenteral drug delivery

Our work also assesses contract manufacturing organisations (CMOs) in that field. There you explore these production service providers:

  • Catalent
  • Hospira One2One
  • Vetter Pharma
  • Baxter
  • Laboratorios Farmacéuticos ROVI
  • Albany Molecular Research Inc (AMRI).

So you assess competitive outlooks of CMOs. You also scan applications for biological drugs (biologics), lyophilisation and dual-chamber syringes.

Value of that market in 2018 - what's possible?

Our analysis predicts overall world revenues for those pre-filled injection devices - the drug delivery technology - will reach $5.9bn in 2018. Those sales will expand further to 2024.

Greater use of biologics and vaccines raise demand for parenteral delivery systems. Many opportunities exist, especially for plastic syringes and ready-to-use containment of labile drugs and other complex pharmaceuticals. The study explains.

What about applications? Incidence of diabetes and expansion of the home healthcare market stimulate demand for pre-filled drug injection products. See how and where.

So medical injection systems giving improved clinical efficacy, safety and convenience will achieve success. There you discover prospects from 2014 to 2024 for that industry.

Ways Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2014-2024 helps

In particular our new investigation gives you this knowledge:

  • Profiles of 19 leading companies - assess products, services, activities, opinions and results
  • Competition and opportunities - explore what affects that industry, finding what influences its sales and determines its future
  • Revenues to 2024 for that market at world level - discover prospects for sales growth of the overall industry and nine of its companies.

That report assesses prospects for companies in each segment via Porter's five forces analysis. It also examines strengths, weaknesses, opportunities and threats (SWOT forces) those organisations face.

Information found nowhere else, benefiting your searches, planning and decisions

That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting recognition for technological and commercial insight.

Our new investigation is for everyone needing analysis of the industry and market for drug delivery via injections. There you find data, trends, opportunities and sales predictions. So please get our report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Overview of Findings
  • 1.2. Structure of the Report
  • 1.3. Research and Analysis Methods

2. The Pre-Filled Injection Devices Market, 2014-2024

  • 2.1. What are Pre-Filled Injection Devices?
  • 2.2. Classification of Top Pre-Filled Injection Device Manufacturers
    • 2.2.1. Glass vs. Plastic Syringes
  • 2.3. Pen Injectors and Auto-Injectors
  • 2.4. Advantages and Disadvantages to Pre-Filled Injection Devices
  • 2.5. The World Pre-Filled Injection Devices Market, 2013
  • 2.6. Pre-Filled Injection Devices Forecast, 2014-2024
  • 2.7. Demand is Greatest in Developed Countries
  • 2.8. Market Drivers and Restraints

3. Leading Pre-Filled Syringe Manufacturers, 2014

  • 3.1. Becton, Dickinson & Co (BD)
    • 3.1.1. BD Has a Broad Pre-Filled Syringe Product Range
    • 3.1.2. BD's Proprietary Product: BD Hypak
    • 3.1.3. BD Neopak: BD's Latest Innovation
    • 3.1.4. BD Sterifill
    • 3.1.5. BD Soluvia Microinjection System
    • 3.1.6. Uniject is a Product for Emerging Markets
    • 3.1.7. BD Physioject: BD's Autoinjector
    • 3.1.8. BD Vystra Disposable Pen is the Company's Latest Pre-Filled Injection System
    • 3.1.9. BD Markets Pen Injectors for Lyophilised Drugs
    • 3.1.10. BD's Proprietary Syringe Safety Systems
    • 3.1.11. Outlook for BD Sales, 2010-2013
    • 3.1.12. BD Revenues by Geographical Location, 2013
    • 3.1.13. BD Medical's Pharmaceutical Systems: Revenue Forecast 2014-2024
    • 3.1.14. SWOT Analysis of BD's Pre-Filled Syringes Market Potential, 2014-2024
  • 3.2. Gerresheimer: A Leading Supplier of Glass and Plastics
    • 3.2.1. Gerresheimer's Pre-Filled Syringe Products, 2014
    • 3.2.2. Ready-To-Fill (RTF) Syringes
    • 3.2.3. Gerresheimer Licensed Polymer Syringes from Taisei Kako
    • 3.2.4. Gerresheimer Began Manufacturing Pen Injectors in 2009
    • 3.2.5. Strong Revenue Growth for Gerresheimer, 2012-2013
    • 3.2.6. Outlook for Gerresheimer's Pre-Filled Injection Devices Market, 2014-2024
    • 3.2.7. SWOT Analysis of Gerresheimer's Pre-Filled Injection Devices Market Potential, 2014-2024
  • 3.3. Schott: One of the World's Leading Manufacturers of Glass Products
    • 3.3.1. Schott Produces over 600 Product Lines
    • 3.3.2. Glass Syringes: syriQ
    • 3.3.3. TopPac Polymer Syringes
    • 3.3.4. Schott's Financial Performance, 2011-2013
    • 3.3.5. SWOT Analysis of Schott's Pre-Filled Syringes Market Potential, 2014-2024
  • 3.4. Nipro Corporation: A Market Leader via its MGlas Acquisition
    • 3.4.1. Outlook for Nipro's Pre-Filled Injectables Market, 2014-2024
    • 3.4.2. SWOT Analysis of Nipro's Pre-Filled Injectables Market Potential, 2014-2024
  • 3.5. The Stevanato Group Among the World Leaders
    • 3.5.1. The Glass Division Includes Nuova Ompi
    • 3.5.2. Nuova Ompi: A Pre-Filled Syringe Specialist
      • 3.5.2.1. EZ-Fill Syringes
      • 3.5.2.2. Extra High Quality (XQ) Syringes
      • 3.5.2.3. Investment in New Mexican Facility
    • 3.5.3. SWOT Analysis of Nuova Ompi's Pre-Filled Syringes Market Potential, 2014-2024
  • 3.6. Unilife Corporation
    • 3.6.1. Pre-filled Syringes for Reconstitution
    • 3.6.2. Autoinjectors: RITA and LISA
    • 3.6.3. Novel Delivery Technologies
    • 3.6.4. Unilife Settles Supply Agreements with Pharma Giants to Improve Market Presence
    • 3.6.5. How Will Unilife Grow over the Forecast Period?
    • 3.6.6. SWOT Analysis of Unilife's Market Potential, 2014-2024
  • 3.7. Pre-Filled Syringe Manufacturers: Porter's Five Forces Analysis, 2014-2024
    • 3.7.1. Rivalry Among Competitors
    • 3.7.2. Manufacturers Striving to Improve Safety Systems
    • 3.7.3. Increasing Product Portfolio Diversity
    • 3.7.4. Threat of New Entrants
    • 3.7.5. Power of Suppliers
    • 3.7.6. Power of Buyers
    • 3.7.7. Threat of Substitutes

4. Leading Pre-Filled Syringe Component Manufacturers, 2014

  • 4.1. Aptar Stelmi: A Pharma Packaging Specialist
    • 4.1.1. Aptar Stelmi's Pre-Filled Syringe Components, 2014
    • 4.1.2. Rigid Needle Shields
    • 4.1.3. Company Acquired Oval Medical to Include Autoinjectors
    • 4.1.4. Financial Progress, 2014-2024
    • 4.1.5. What Are the Strengths and Weaknesses of Aptar Stelmi in the Pre-Filled Syringes Market?
  • 4.2. The Datwyler Group
    • 4.2.1. Datwyler's Pre-Filled Syringe Components, 2014
    • 4.2.2. Omniflex Coating: Alternative to Silicone
    • 4.2.3. Expansion of FirstLine Range
    • 4.2.4. The Sealing Solutions Division
      • 4.2.4.1. Demand from Vaccine and Insulin Manufacturers Driving Growth
    • 4.2.5. Outlook of Datwyler's Pharma Packaging Division, 2014-2024
    • 4.2.6. SWOT Analysis of Datwyler's Pre-Filled Syringe Business: Market Potential, 2014-2024
  • 4.3. West Pharmaceutical Services
    • 4.3.1. West's Packaging Systems
    • 4.3.2. West's Delivery Systems
      • 4.3.2.1. Daikyo CZ: The First Silicone-Free Polymer Syringe
      • 4.3.2.2. SmartDose: A Novel Patch Injector
    • 4.3.3. West Also Develops Autoinjectors and Self Injectors
    • 4.3.4. MixJect: Addressing Lyophilised Drugs
    • 4.3.5. West's Financial Performance in 2013
    • 4.3.6. Outlook for West's Pre-Filled Syringes Market, 2014-2024
    • 4.3.7. SWOT Analysis of West's Pre-Filled Syringe Market Potential, 2014-2024
  • 4.4. Pre-Filled Syringe Component Manufacturers: Porter's Five Forces Analysis, 2014-2024
    • 4.4.1. Rivalry Among Competitors
      • 4.4.1.1. Emerging National Markets Will Become More Important
    • 4.4.2. Threat of New Entrants
    • 4.4.3. Power of Suppliers
    • 4.4.4. Power of Buyers
    • 4.4.5. Threat of Substitutes

5. Leading Pre-Filled Syringe Contract Manufacturers, 2014

  • 5.1. Catalent: The World's Leading CMO
    • 5.1.1. High Pre-Filled Syringe Contract Manufacturing Capabilities
    • 5.1.2. Outlook for Catalent's Pre-Filled Syringes Services, 2014-2024
    • 5.1.3. SWOT Analysis of Catalent's Contract Pre-Filled Syringe Filling Potential, 2014-2024
  • 5.2. Hospira One2One Offers Contract Manufacturing Services
    • 5.2.1. Hospira's Pre-Filled Syringes, 2014
    • 5.2.2. Speciality Injectable Pharmaceuticals is the Largest Division
    • 5.2.3. Outlook for Hospira's Contract Manufacturing Services, 2014-2024
    • 5.2.4. SWOT Analysis of Hospira One2One Market Potential, 2014-2024
  • 5.3. Vetter Pharma
    • 5.3.1. An Injectable Manufacturing Specialist
    • 5.3.2. Vetter Expands in The US and Germany
    • 5.3.3. SWOT Analysis of Vetter's Contract Pre-Filled Syringe Filling Capacitates, 2014-2024
  • 5.4. Baxter Has its Own CMO
    • 5.4.1. BioPharma Solutions
    • 5.4.2. SWOT Analysis of BioPharma Solution's Services, 2014-2024
  • 5.5. Laboratorios Farmacéuticos ROVI
    • 5.5.1. ROVI's Pre-Filled Syringe Capabilities, 2014
    • 5.5.2. SWOT Analysis of ROVI's Contract Manufacturing Potential, 2014-2024
  • 5.6. Albany Molecular Research Inc (AMRI)
    • 5.6.1. AMRI's Financial Performance in 2013
    • 5.6.2. SWOT Analysis of AMRI's Contract Manufacturing Services, 2014-2024
  • 5.7. Porter's Five Forces Analysis of Pre-Filled Syringe Contract Manufacturers, 2014-2024
    • 5.7.1. Rivalry Among Competitors
    • 5.7.2. Threat of New Entrants
    • 5.7.3. Power of Suppliers
    • 5.7.4. Power of Buyers
    • 5.7.5. Threat of Substitutes

6. Leading Pen Injectors and Autoinjector Manufacturers, 2014

  • 6.1. Ypsomed: Diabetes Specialists for over 25 Years
    • 6.1.1. Yposomed's Long List of Pen Injectors and Autoinjectors, 2014
    • 6.1.2. YpsoPen: A Reusable Insulin Pen
    • 6.1.3. ServoPen
    • 6.1.4. UnoPen Range
    • 6.1.5. LyoTwist Injectors for Lyophilised Drugs
    • 6.1.6. Ypsomed Markets Two Autoinjectors
    • 6.1.7. VarioJect
    • 6.1.8. Ypsomed Outlook, 2014-2024
    • 6.1.9. What Are Ypsomed's Strengths and Weaknesses?
  • 6.2. Haselmeier: A Specialist in Self-Injection Devices
    • 6.2.1. Axis Pen Systems
    • 6.2.2. i-Pen: Haselmeier's Lead Product
    • 6.2.3. Penlet Used For the Administration of Enoxaparin
    • 6.2.4. The SoftPen Platform
    • 6.2.5. SWOT Analysis of Haselmeier's Injectables Market Potential, 2014-2024
  • 6.3. SHL Group
    • 6.3.1. Divisions and Activities of that Company
      • 6.3.1.1. A Broad Product Portfolio, 2014
      • 6.3.1.2. Amber Autoinjector: SHL's Later Innovation
      • 6.3.1.3. Molly Autoinjector
      • 6.3.1.4. DAI Series Most Successful
    • 6.3.2. SHL Group Continues to Grow in Taiwan
    • 6.3.3. SWOT Analysis of SHL Group's Market Potential, 2014-2024
  • 6.4. Owen Mumford
    • 6.4.1. Autoinjector and Pen Injector Overview
    • 6.4.2. The Autopen Series
    • 6.4.3. Unifine Pentips for Improved Comfort
    • 6.4.4. How Does Owen Mumford Compete?
    • 6.4.5. SWOT Analysis of Owen Mumford's Market Potential, 2014-2024
  • 6.5. Porter's Five Forces Analysis of the Pen Injector and Autoinjector Manufacturers, 2014-2024
    • 6.5.1. Rivalry Among Competitors
    • 6.5.2. Threat of New Entrants
    • 6.5.3. Power of Suppliers
    • 6.5.4. Power of Buyers
    • 6.5.5. Threat of Substitutes

7. Research Interviews

  • 7.1. Interview with Simon Williams, Business Development at Duoject Medical Systems, Quebec, Canada
    • 7.1.1. The Current Pre-Filled Injectables Market
    • 7.1.2. What Does Duoject Offer?
    • 7.1.3. Pre-Filled Syringes Will Continue to Dominate the Market
  • 7.2. Interview with a Respondent from a Leading Company in the Pre-Filled Injection Devices Market
    • 7.2.1. The Potential of the Pre-Filled Injections Market
    • 7.2.2. Changing Demands

8. Conclusions

  • 8.1. The Pre-Filled Injection Devices Market in 2013
  • 8.2. Leading Pre-Filled Injection Device Manufacturers in 2014
  • 8.3. The World Pre-Filled Injection Devices Market: Predictions to 2024
  • 8.4. Outlook for the Pre-Filled Injection Device Manufacturers 2014-2024
    • 8.4.1. Emerging Countries Will Play Pivotal Role
  • 8.5. Future of the Pre-Filled Injection Device Manufacturers Market

List of Tables

  • Table 2.1: Pre-Filled Injection Devices: Sub-Market Revenues ($m), Units (m), 2013
  • Table 2.2: Pre-Filled Injection Devices: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 2.3: Pre-Filled Injection Devices: Revenue Forecasts by Segment ($m, CAGR %, Market Share %), 2013, 2018, 2024
  • Table 2.4: Pre-Filled Injection Devices Market by Region: Revenues ($m) and Market Shares (%), 2013
  • Table 3.1: BD: Key Facts, 2014
  • Table 3.2: BD Segments and Products, 2014
  • Table 3.3: BD Revenues by Segment ($m), 2010-2013
  • Table 3.4: BD Medical: Revenues by Segment ($m), 2010-2013
  • Table 3.5: BD: Pharmaceutical Systems Forecast, Revenue ($m), AGR (%), CAGR (%), 2013-2024
  • Table 3.6: BD Injection Devices: SWOT Analysis 2014-2024
  • Table 3.7: Gerresheimer: Key Facts, 2014
  • Table 3.8: Gerresheimer Segments and Products, 2013
  • Table 3.9: Restructured Gerresheimer Segments, 2014
  • Table 3.10: Gerresheimer Segments Revenues ($m), 2012, 2013
  • Table 3.11: Gerresheimer Pre-filled Injection Systems: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 3.12: Gerresheimer Injection Devices: SWOT Analysis 2014-2024
  • Table 3.13: Schott: Key Facts, 2014
  • Table 3.14: Schott: Revenues ($m), 2011-2013
  • Table 3.15: Schott: Revenue Breakdown by Region ($m) with Revenue Share, 2013
  • Table 3.16: Schott Pre-filled Injection Devices: SWOT Analysis, 2014-2024
  • Table 3.17: Nipro: Key Facts, 2014
  • Table 3.18: Nipro: Revenues ($m), 2011-2013
  • Table 3.19: Nipro: Revenue Breakdown by Region ($m) with Revenue Share, 2013
  • Table 3.20: Nipro Pre-filled Injection Devices: SWOT Analysis, 2014-2024
  • Table 3.21: Stevanato Group: Key Facts, 2014
  • Table 3.22: Stevanato Group's Glass Division: Breakdown by Companies, 2014
  • Table 3.23: Nuova Ompi Pre-filled Injection Devices: SWOT Analysis, 2014-2024
  • Table 3.24: Unilife: Key Facts, 2014
  • Table 3.25: Unilife: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 3.26: Unilife: SWOT Analysis, 2014-2024
  • Table 3.27: Pre-Filled Syringes: Leading Product Comparisons, 2014
  • Table 3.28: Leading Pre-Filled Syringe Manufacturers: Comparative Product Ranges, 2014
  • Table 4.1: Aptar Stelmi: Key Facts, 2014
  • Table 4.2: Aptar Stelmi: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 4.3: Aptar Stelmi: SWOT Analysis, 2014-2024
  • Table 4.4: Datwyler Group: Key Facts, 2014
  • Table 4.5: Datwyler Group: Sealing Solutions Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 4.6: Datwyler Group: SWOT Analysis, 2014-2024
  • Table 4.7: West Pharmaceutical Services: Key Facts, 2014
  • Table 4.8: West Pharmaceuticals: Revenue Breakdown by Division ($m), 2012-2013
  • Table 4.9: West Pharmaceuticals: Pre-filled Injection Devices Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 4.10: West Pharmaceuticals: SWOT Analysis, 2014-2024
  • Table 5.1: Catalent: Key Facts, 2014
  • Table 5.2: Catalent: Revenue Breakdown by Division ($m, Revenue Share %), 2013
  • Table 5.3: Catalent: Revenue Breakdown by Division ($m, AGR %), 2012-2013
  • Table 5.4: Catalent: Pre-filled Injection Devices Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 5.5: Catalent: SWOT Analysis, 2014-2024
  • Table 5.6: Hospira: Key Facts, 2014
  • Table 5.7: Hospira: Revenue Breakdown by Division ($m, AGR %), 2012-2013
  • Table 5.8: Hospira: Pre-filled Injection Devices Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
  • Table 5.9: Hospira: SWOT Analysis, 2014-2024
  • Table 5.10: Vetter Pharma: Key Facts, 2014
  • Table 5.11: Vetter Pharma: SWOT Analysis, 2014-2024
  • Table 5.12: Baxter: Key Facts, 2014
  • Table 5.13: Baxter: Revenue Breakdown by Division ($m, AGR %), 2011-2013
  • Table 5.14: Baxter's BioPharma Solutions: SWOT Analysis, 2014-2024
  • Table 5.15: Laboratorios Farmacéuticos ROVI: Key Facts, 2014
  • Table 5.16: ROVI: SWOT Analysis, 2014-2024
  • Table 5.17: AMRI: Key Facts, 2014
  • Table 5.18: AMRI: CM Revenue Breakdown by Division ($m, AGR %), 2012-2013
  • Table 5.19: AMRI: SWOT Analysis, 2014-2024
  • Table 6.1: Ypsomed: Key Facts, 2014
  • Table 6.2: Ypsomed Product Portfolio, 2014
  • Table 6.3: Selected Pharmaceutical Partners for Ypsomed's Pen Injectors, 2014
  • Table 6.4: Ypsomed: Revenue ($m) by Segment, 2010-2013
  • Table 6.5: Ypsomed: Delivery Devices Forecast, Revenue ($m), AGR (%), CAGR (%), 2013-2024
  • Table 6.6: Ypsomed Injection Devices: SWOT Analysis, 2014-2024
  • Table 6.7: Haselmeier: Key Facts, 2014
  • Table 6.8: Selected Partners for the i-Pen, 2014
  • Table 6.9: Haselmeier: SWOT Analysis, 2014-2024
  • Table 6.10: SHL Group: Key Facts, 2014
  • Table 6.11: SHL Group Product Portfolio, 2014
  • Table 6.12: SHL Group: SWOT Analysis, 2014-2024
  • Table 6.13: Owen Mumford: Key Facts, 2014
  • Table 6.14: Owen Mumford: SWOT Analysis, 2014-2024
  • Table 6.15: Other Pen Injectors and Autoinjector Manufacturers, 2014
  • Table 8.1: Pre-Filled Injection Devices Market: Overall Revenue Forecast by Submarkets ($m), and Market Shares (%), 2013, 2018 and 2024

List of Figures

  • Figure 2.1: Pre-Filled Injection Devices: Sub-Market Shares (%), 2013
  • Figure 2.2: Pre-Filled Injection Devices: Sub-Market Revenues ($m) and Units (m), 2013
  • Figure 2.3: Pre-Filled Injection Devices: Revenue Forecast ($m), 2013-2024
  • Figure 2.4: Pre-Filled Injection Devices: Submarket Revenue Forecasts by Segment ($m), 2013, 2018, 2024
  • Figure 2.5: Pre-Filled Injection Devices: Sub-Market Shares (%), 2018
  • Figure 2.6: Pre-Filled Injection Devices: Sub-Market Shares (%), 2024
  • Figure 2.7: Pre-Filled Injection Devices Market Shares by Region (%), 2013
  • Figure 2.8: Pre-Filled Injection Devices Market: Drivers and Restraints, 2014-2024
  • Figure 3.1: BD Revenues by Segment ($m), 2010-2013
  • Figure 3.2: BD Segments by Market Share (%), 2013
  • Figure 3.3: BD Medical Revenues by Segment ($m), 2010-2013
  • Figure 3.4: BD Medical Segments by Market Share (%), 2013
  • Figure 3.5: BD Revenues by Geographical Location ($m) and Revenue Shares (%), 2012-2013
  • Figure 3.6: BD Pharmaceutical Systems: Forecast, Revenue ($m), 2013-2024
  • Figure 3.7: Gerresheimer Pharmaceutical Systems Revenue ($m), 2012-2013
  • Figure 3.8: Gerresheimer Pre-filled Injection Systems: Revenue Forecast ($m), 2013-2024
  • Figure 3.9: Schott: Revenue ($m), 2011, 2012, 2013
  • Figure 3.10: Schott: Revenue Breakdown by Region ($m) and Revenue Share, 2013
  • Figure 3.11: Nipro: Revenues by Segment ($m), 2013
  • Figure 3.12: Nipro: Revenue Breakdown by Region ($m) and Revenue Share, 2013
  • Figure 3.13: Unilife: Revenue Forecast ($m), 2013-2024
  • Figure 3.14: Porter's Five Forces Analysis of Pre-Filled Syringe Manufacturers, 2014-2024
  • Figure 4.1: Aptar Stelmi: Revenue Shares ($m, %), 2013
  • Figure 4.2: Aptar Stelmi: Revenue Forecast ($m), 2013-2024
  • Figure 4.3: Datwyler Group: Sealing Solutions Division Revenues ($m), 2012-2013
  • Figure 4.4: Datwyler Group: Sealing Solutions Division Revenue Forecast ($m), 2013-2024
  • Figure 4.5: West Pharmaceuticals: Revenue Breakdown by Division ($m, AGR %) 2012-2013
  • Figure 4.6: West Pharmaceuticals: Breakdown by Revenue Share (%), 2013
  • Figure 4.7: West Pharmaceuticals: Pre-filled Injection Devices Revenue Forecast ($m), 2013-2024
  • Figure 4.8: Porter's Five Forces Analysis of Pre-Filled Syringes Component Manufacturers, 2014-2024
  • Figure 5.1: Catalent: Breakdown by Revenue Share (%), 2013
  • Figure 5.2: Catalent: Revenue by Division ($m), 2012-2013
  • Figure 5.3: Catalent: Pre-filled Injection Devices Revenue Forecast ($m), 2013-2024
  • Figure 5.4: Hospira: Breakdown by Revenue Share ($m), 2013
  • Figure 5.5: Hospira: Pre-filled Injection Devices Revenue Forecast ($m), 2013-2024
  • Figure 5.6: Baxter: Revenue Shares ($m, %), 2013
  • Figure 5.7: Baxter: BioPharma Solutions Revenues ($m), 2011-2013
  • Figure 5.8: AMRI: Revenue Breakdown by Division ($m), 2012-2013
  • Figure 5.9: Porter's Five Forces Analysis of Pre-Filled Syringes Contract Manufacturers, 2014-2024
  • Figure 6.1: Ypsomed Revenue ($m) by Segment, 2010-2013
  • Figure 6.2: Ypsomed: Pre-filled Syringes Revenue ($m) Forecast, 2013-2024
  • Figure 6.3: Porter's Five Forces Analysis of Pen Injector and Auto-Injector Manufacturers, 2014-2024
  • Figure 8.1: Pre-Filled Injection Devices Market: Overall Revenue Forecasting with Submarket ($m), 2013, 2018 and 2024

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Actavis (formerly Watson Pharmaceuticals)
  • Aflamtic (part of Stevanato Group)
  • Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
  • Albany Molecular Research (AMRI)
  • American Stelmi
  • American Stelmi (part of Aptar Stelmi)
  • Amgen
  • Amylin Pharmaceuticals
  • Antares Pharma
  • Aptar Stelmi (part of Aptargroup)
  • AptarGroup
  • AstraZeneca
  • B. Braun Medical
  • Baxter BioPharma Solutions (part of Baxter)
  • Baxter International
  • Bayer
  • BD Medico
  • Becton, Dickinson and Company (BD)
  • Berlin-Chemie (part of Menarini Group)
  • Bespak Injectables (formerly The Medical House)
  • Biocon
  • Biogen Idec
  • Blackstone Group
  • Bristol-Myers Squibb
  • Cambridge Consultants
  • Cardinal Health
  • Carl Zeiss Foundation
  • Catalent
  • Chemisch-Pharmazeutisches Laboratorium Ravensburg
  • Daikyo Seiko
  • Datwyler
  • DiaExpert
  • Disetronic Group (part of Roche)
  • Dong-A Pharmaceutical
  • Dongbao
  • Duoject Medical Systems
  • DuPont
  • Elcam Medical
  • Eli Lilly
  • European Commission
  • European Medicines Agency (EMA)
  • Ferring Pharmaceuticals
  • Food and Drug Administration (FDA) [US]
  • Future Injection Technologies
  • Genentech (part of Roche)
  • Gerresheimer
  • GlaxoSmithKline (GSK)
  • Hankook Sealtech
  • Haselmeier
  • Hikma Pharmaceuticals
  • Hospira
  • Hospira One2One (part of Hospira)
  • Hyaluron Contract Manufacturing (HCM, part of AMRI)
  • Incepta Pharmaceuticals
  • Insulet
  • International Diabetes Federation Europe (IDF)
  • Jabil Circuit
  • Janssen Biotech (part of J&J)
  • Johnson & Johnson (J&J)
  • Korea Food and Drug Administration (KFDA)
  • Laboratorios Farmacéuticos ROVI
  • LifeScan
  • Lupin Limited
  • Maxxon
  • McKesson
  • Medical Glass (part of Stevanato Group)
  • Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
  • MedImmune
  • Medimop Medical Projects (part of West Pharmaceutical Services)
  • Menarini Group
  • Merck Serono
  • Merck & Co.
  • Merck KGaA
  • MG Sterile Products (part of Nipro)
  • MGlas (part of Nipro)
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • MJ Biopharma
  • Mylife DiabetesCare
  • National Institute for Health and Care Services (NICE)
  • Neutral Glass and Allied Industries
  • Nipro Europe (part of Nipro)
  • Nipro Medical Corporation
  • Nipro MGlass (part of Nipro)
  • Novartis
  • Novo Nordisk
  • Nuova Ompi
  • Nycomed (part of Takeda)
  • Nypro
  • Occupational Safety and Health Administration (OSHA) [US]
  • Ompi of America (part of Stevanato Group)
  • Optrel (part of Stevanato Group)
  • OrbiMed
  • Oval Medical
  • Owen Mumford
  • PA Consulting Group
  • PATH
  • Pema Holding
  • Pfizer
  • Pharma-Pen (part of West Pharmaceutical Services)
  • Pharmstandard
  • Phillips Medisize
  • Plastef Investissements
  • Polfa-Tarchomin
  • Primequal
  • Revolutions Medical
  • RevVac
  • Rexam
  • Roche
  • ROVI CM (part of Laboratorios Farmacéuticos ROVI)
  • Safety Syringes (part of BD)
  • Sandoz (part of Novartis)
  • Sanex Packaging Connections
  • Sanofi
  • Sanofi Pasteur
  • Savient Pharmaceuticals
  • Schering-Plough (part of Merck & Co.)
  • Schott
  • Schott Kaisha
  • Sentry BioPharma Services
  • Shanghai Fosun Pharmaceutical
  • SHL Group
  • Spami (part of Stevanato Group)
  • Square Pharmaceuticals
  • Stallergenes
  • Stelmi Asia (part of Aptar Stelmi)
  • Stevanato Group
  • Sungwon Medical
  • Swedish Orphan Biovitrum (Sobi)
  • Taisei Kako
  • Teva Pharmaceutical Industries
  • The Tech Group (part of West Pharmaceutical Services)
  • Tonghua Dongbao Pharmaceutical
  • Triveni Polymers
  • UCB
  • Unilife Corporation
  • US Agency for International Development
  • Vetter Pharma
  • West Company Mexico
  • West Pharmaceutical India Packaging Private (part of West Pharmaceutical Services)
  • West Pharmaceutical Services
  • Wockhardt
  • World Health Organization (WHO)
  • YDS Ypsomed Delivery Systems
  • Ypsomed
  • Zeon Corporation
Back to Top